Telomerase reverse transcriptase promoter mutation– and O6-methylguanine DNA methyltransferase promoter methylation–mediated sensitivity to temozolomide in isocitrate dehydrogenase–wild-type glioblastoma: is there a link?
Open Access
- 1 April 2021
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 147, 84-94
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Krebshilfe
This publication has 40 references indexed in Scilit:
- Highly Recurrent TERT Promoter Mutations in Human MelanomaScience, 2013
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trialThe Lancet Oncology, 2012
- Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastomaNature, 2012
- Predictive impact of MGMT promoter methylation in glioblastoma of the elderlyInternational Journal of Cancer, 2011
- Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomasInternational Journal of Cancer, 2011
- Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma NetworkJournal of Clinical Oncology, 2009
- Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma PatientsClinical Cancer Research, 2009
- Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomasActa Neuropathologica, 2009
- Telomerase and cancer therapeuticsNature Reviews Cancer, 2008
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005